195 related articles for article (PubMed ID: 36965280)
1. A ciprofloxacin derivative with four mechanisms of action overcomes paclitaxel resistance in p53-mutant and MDR1 gene-expressing type II human endometrial cancer.
Alhaj-Suliman SO; Naguib YW; Wafa EI; Saha S; Ebeid K; Meng X; Mohammed HH; Abuo-Rahma GEA; Yang S; Salem AK
Biomaterials; 2023 May; 296():122093. PubMed ID: 36965280
[TBL] [Abstract][Full Text] [Related]
2. Ciprofloxacin Derivative-Loaded Nanoparticles Synergize with Paclitaxel Against Type II Human Endometrial Cancer.
Naguib YW; Alhaj-Suliman SO; Wafa EI; Saha S; Ebeid K; Mohammed HHH; Abdel-Rahman SA; Abuo-Rahma GEA; Geary SM; Salem AK
Small; 2023 Jul; ():e2302931. PubMed ID: 37525558
[TBL] [Abstract][Full Text] [Related]
3. Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.
Meng X; Laidler LL; Kosmacek EA; Yang S; Xiong Z; Zhu D; Wang X; Dai D; Zhang Y; Wang X; Brachova P; Albitar L; Liu D; Ianzini F; Mackey MA; Leslie KK
Gynecol Oncol; 2013 Mar; 128(3):461-9. PubMed ID: 23146687
[TBL] [Abstract][Full Text] [Related]
4. Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer.
Albitar L; Carter MB; Davies S; Leslie KK
Gynecol Oncol; 2007 Jul; 106(1):94-104. PubMed ID: 17490733
[TBL] [Abstract][Full Text] [Related]
5. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors.
Wang C; Guan W; Peng J; Chen Y; Xu G; Dou H
Acta Biomater; 2020 Feb; 103():247-258. PubMed ID: 31846802
[TBL] [Abstract][Full Text] [Related]
6. p53-dependent apoptosis is essential for the antitumor effect of paclitaxel response to DNA damage in papillary thyroid carcinoma.
Wu W; Wei T; Li Z; Zhu J
Int J Med Sci; 2021; 18(14):3197-3205. PubMed ID: 34400889
[TBL] [Abstract][Full Text] [Related]
7. Synthetically lethal nanoparticles for treatment of endometrial cancer.
Ebeid K; Meng X; Thiel KW; Do AV; Geary SM; Morris AS; Pham EL; Wongrakpanich A; Chhonker YS; Murry DJ; Leslie KK; Salem AK
Nat Nanotechnol; 2018 Jan; 13(1):72-81. PubMed ID: 29203914
[TBL] [Abstract][Full Text] [Related]
8. Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor.
Hasegawa K; Ishikawa K; Kawai S; Torii Y; Kawamura K; Kato R; Tsukada K; Udagawa Y
Oncol Rep; 2013 Dec; 30(6):2937-44. PubMed ID: 24100466
[TBL] [Abstract][Full Text] [Related]
9. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
[TBL] [Abstract][Full Text] [Related]
10. Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer
O'Donnell J; Zhao Z; Buckingham L; Hao T; Suo H; Zhang X; Fan Y; John C; Deng B; Shen X; Sun W; Secord AA; Zhou C; Bae-Jump VL
Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37503790
[TBL] [Abstract][Full Text] [Related]
11. Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent.
Luo W; Wu F; Elmaoued R; Beck BB; Fischer E; Meng X; Leslie KK; Dai D
Int J Oncol; 2010 Nov; 37(5):1187-94. PubMed ID: 20878066
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo.
Zuco V; De Cesare M; Cincinelli R; Nannei R; Pisano C; Zaffaroni N; Zunino F
PLoS One; 2011; 6(12):e29085. PubMed ID: 22194993
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
Byron SA; Loch DC; Pollock PM
Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
[TBL] [Abstract][Full Text] [Related]
14. Glaucarubinone sensitizes KB cells to paclitaxel by inhibiting ABC transporters via ROS-dependent and p53-mediated activation of apoptotic signaling pathways.
Karthikeyan S; Hoti SL; Nazeer Y; Hegde HV
Oncotarget; 2016 Jul; 7(27):42353-42373. PubMed ID: 27304668
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategies to overcome taxane resistance in cancer.
Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
[TBL] [Abstract][Full Text] [Related]
16. Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.
Mao K; Liu F; Liu X; Khuri FR; Marcus AI; Li M; Zhou W
Lung Cancer; 2015 May; 88(2):131-8. PubMed ID: 25769882
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the potential theranostic role of KDM5B/miR-29c signaling axis in paclitaxel resistant endometrial carcinoma.
Li L; Shou H; Wang Q; Liu S
Gene; 2019 Apr; 694():76-82. PubMed ID: 30658067
[TBL] [Abstract][Full Text] [Related]
18. The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells.
Ji L; Liu X; Zhang S; Tang S; Yang S; Li S; Qi X; Yu S; Lu L; Meng X; Liu Z
Molecules; 2017 Oct; 22(11):. PubMed ID: 29072615
[TBL] [Abstract][Full Text] [Related]
19. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
20. Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells.
Tanaka T; Toujima S; Tanaka J
Int J Oncol; 2012 Nov; 41(5):1837-44. PubMed ID: 22923148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
